Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

May 21, 2025 08:45 ET | Source: Silexion Therapeutics Corp

Silexion Therapeutics Completes Key Preclinical Studies Exploring SIL204’s Potential Impact on Colorectal and Lung Cancer

GRAND CAYMAN, Cayman Islands, May 21, 2025 (GLOBE NEWSWIRE) -- Silexion Therapeutics Corp (NASDAQ: SLXN) (“Silexion” or the “Company”), a clinical-stage biotech company developing RNA interference...
May 13, 2025 16:45 ET | Source: Silexion Therapeutics Corp

Silexion Therapeutics Reports First Quarter 2025 Financial Results and Provides Business Update

GRAND CAYMAN, Cayman Islands, May 13, 2025 (GLOBE NEWSWIRE) -- Silexion Therapeutics Corp. (NASDAQ: SLXN) (“Silexion” or the “Company”), a clinical-stage biotech company developing RNA interference...
April 23, 2025 09:20 ET | Source: Silexion Therapeutics Corp

Silexion Therapeutics Announces Collaboration with Global Therapeutics Leader Catalent on Advanced siRNA Formulation Development & Clinical Manufacturing Activities

Grand Cayman, Cayman Islands, April 23, 2025 (GLOBE NEWSWIRE) -- Silexion Therapeutics Corp. (NASDAQ: SLXN) (“Silexion” or the “Company”), a clinical-stage biotechnology company pioneering RNA...
March 28, 2025 08:30 ET | Source: Silexion Therapeutics Corp

Silexion Therapeutics Unveils Innovative Expanded Development Plan for SIL204 Based on Recent Groundbreaking Preclinical Data

Grand Cayman, Cayman Islands, March 28, 2025 (GLOBE NEWSWIRE) -- Silexion Therapeutics Corp. (NASDAQ: SLXN) (“Silexion” or the “Company”), a clinical-stage biotechnology company pioneering RNA...
March 21, 2025 08:30 ET | Source: Silexion Therapeutics Corp

Silexion Therapeutics Announces Completion of Innovative Expanded Development Plan for SIL204 which will be unveiled at the 2025 NeauxCancer Conference

Grand Cayman, Cayman Islands, March 21, 2025 (GLOBE NEWSWIRE) -- Silexion Therapeutics Corp. (“Silexion” or the “Company”), a clinical-stage biotechnology company pioneering RNA interference (RNAi)...
March 18, 2025 16:29 ET | Source: Silexion Therapeutics Corp

Silexion Therapeutics Reports Full Year 2024 Financial Results and Provides Business Update

Grand Cayman, Cayman Islands, March 18, 2025 (GLOBE NEWSWIRE) -- Silexion Therapeutics Corp. (NASDAQ: SLXN) ("Silexion" or the "Company"), a clinical-stage biotechnology company pioneering RNA...
March 05, 2025 08:30 ET | Source: Silexion Therapeutics Corp

Silexion Therapeutics Reports Groundbreaking Positive Initial Data from Systemic Administration of SIL204 in Orthotopic Pancreatic Cancer Models

Grand Cayman, Cayman Islands, March 05, 2025 (GLOBE NEWSWIRE) -- Silexion Therapeutics Corp. (NASDAQ: SLXN) ("Silexion" or the "Company"), a clinical-stage biotechnology company pioneering RNA...
February 25, 2025 08:30 ET | Source: Silexion Therapeutics Corp

Silexion Therapeutics Announces Completion of Initial Study in Orthotopic Pancreatic Cancer Models Evaluating Systemic Administration of SIL-204

Grand Cayman, Cayman Islands, Feb. 25, 2025 (GLOBE NEWSWIRE) -- Silexion Therapeutics Corp. (NASDAQ: SLXN) ("Silexion" or the "Company"), a clinical-stage biotechnology company pioneering RNA...
February 03, 2025 07:30 ET | Source: FACT.MR

Non-Infectious Macular Edema Treatment Market is Projected to Expand at 6.9% CAGR to US$ 29.6 Billion by 2034 | Fact.MR Report

Rockville, MD, Feb. 03, 2025 (GLOBE NEWSWIRE) -- The global non-infectious macular edema treatment market is anticipated to secure a valuation of US$ 15,121.9 million in 2024. The global market is...
January 29, 2025 17:30 ET | Source: Silexion Therapeutics Corp

Silexion Therapeutics Announces Exercise of Warrants for $3.3 Million Gross Proceeds

Cayman Islands, January 29, 2025 -- Silexion Therapeutics Corp. (NASDAQ: SLXN) (“Silexion Therapeutics” or the “Company”), a clinical-stage biotech developing RNA interference (RNAi) therapies for...

Next Page keyboard_arrow_right